These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
123 related items for PubMed ID: 2143459
1. Effect of isradipine, a new calcium antagonist on the lipid profile in patients with hypertension. Samuel P. Cor Vasa; 1990; 32(2 Suppl 1):35-41. PubMed ID: 2143459 [Abstract] [Full Text] [Related]
2. Effects of isradipine, a new calcium antagonist, versus hydrochlorothiazide on serum lipids and apolipoproteins in patients with systemic hypertension. Samuel P, Kirkendall W, Schaefer EJ, Chin B, Schoenfeld BH, Gonasun LM, Lieberman S. Am J Cardiol; 1988 Nov 15; 62(16):1068-71. PubMed ID: 2973219 [Abstract] [Full Text] [Related]
3. Long-term lipid profiles with isradipine and hydrochlorothiazide treatment in elderly hypertensive patients. Stein GH, Matthews K, Bannatyne RE, Quay G, Lopez L, McCarley D. J Cardiovasc Pharmacol; 1990 Nov 15; 15 Suppl 1():S90-2. PubMed ID: 1695313 [Abstract] [Full Text] [Related]
4. Metabolic outcome during 1 year in newly detected hypertensives: results of the Antihypertensive Treatment and Lipid Profile in a North of Sweden Efficacy Evaluation (ALPINE study). Lindholm LH, Persson M, Alaupovic P, Carlberg B, Svensson A, Samuelsson O. J Hypertens; 2003 Aug 15; 21(8):1563-74. PubMed ID: 12872052 [Abstract] [Full Text] [Related]
5. Influence of combination of captopril and hydrochlorothiazide on plasma lipids, lipoproteins and apolipoproteins in primary hypertension. Lacourcière Y, Gagné C. J Hum Hypertens; 1993 Apr 15; 7(2):149-52. PubMed ID: 8510087 [Abstract] [Full Text] [Related]
6. Metabolic, hematological, and cardiac effects of long-term isradipine treatment in mild-to-moderate essential hypertension. Meriç M, Gören T, Atilgan D, Eren N, Cubukçu A, Koylan N. J Cardiovasc Pharmacol; 1992 Apr 15; 19 Suppl 3():S58-60. PubMed ID: 1376837 [Abstract] [Full Text] [Related]
7. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial. Pearson T, Denke M, McBride P, Battisti WP, Brady WE, Palmisano J. Am J Geriatr Pharmacother; 2005 Dec 15; 3(4):218-28. PubMed ID: 16503317 [Abstract] [Full Text] [Related]
8. Isradipine vs propranolol in hydrochlorothiazide-treated hypertensives. A multicenter evaluation. Prisant LM, Carr AA, Nelson EB, Winer N, Velasquez MT, Gonasun LM. Arch Intern Med; 1989 Nov 15; 149(11):2453-7. PubMed ID: 2530945 [Abstract] [Full Text] [Related]
9. Effects of indapamide versus hydrochlorothiazide on plasma lipids and lipoproteins in hypertensive patients: a direct comparison. Spence JD, Huff M, Barnett PA. Can J Clin Pharmacol; 2000 Nov 15; 7(1):32-7. PubMed ID: 10822211 [Abstract] [Full Text] [Related]
10. The effects of antihypertensive combination therapy on lipid and glucose metabolism: hydrochlorothiazide plus sotalol vs. hydrochlorothiazide plus captopril. Middeke M, Richter WO, Schwandt P, Holzgreve H. Int J Clin Pharmacol Ther; 1997 Jun 15; 35(6):231-4. PubMed ID: 9208337 [Abstract] [Full Text] [Related]
11. Effects of manidipine/delapril versus olmesartan/hydrochlorothiazide combination therapy in elderly hypertensive patients with type 2 diabetes mellitus. Fogari R, Derosa G, Zoppi A, Rinaldi A, Preti P, Lazzari P, Mugellini A. Hypertens Res; 2008 Jan 15; 31(1):43-50. PubMed ID: 18360017 [Abstract] [Full Text] [Related]
12. Efficacy and tolerability of combination therapy with valsartan plus hydrochlorothiazide compared with amlodipine monotherapy in hypertensive patients with other cardiovascular risk factors: the VAST study. Ruilope LM, Malacco E, Khder Y, Kandra A, Bönner G, Heintz D. Clin Ther; 2005 May 15; 27(5):578-87. PubMed ID: 15978306 [Abstract] [Full Text] [Related]
13. Serum lipoproteins during treatment with antihypertensive drugs. Weidmann P, de Courten M, Ferrari P, Böhlen L. J Cardiovasc Pharmacol; 1993 May 15; 22 Suppl 6():S98-105. PubMed ID: 7508069 [Abstract] [Full Text] [Related]
15. Serum lipoprotein profile under different antihypertensive therapy. Youssef S, Osman L, Sabbour MS. Int J Clin Pharmacol Res; 1992 Dec 15; 12(3):109-16. PubMed ID: 1473876 [Abstract] [Full Text] [Related]
16. Review of the international literature on isradipine in hypertension (Lomir/Dynacirc). Soland FX. Cor Vasa; 1990 Dec 15; 32(2 Suppl 1):61-72. PubMed ID: 2143461 [No Abstract] [Full Text] [Related]
17. Antihypertensive drugs and blood lipids: the Oslo study. Leren P, Eide I, Foss OP, Helgeland A, Hjermann I, Holme I, Kjeldsen SE, Lund-Larsen PG. J Cardiovasc Pharmacol; 1982 Dec 15; 4 Suppl 2():S222-4. PubMed ID: 6177960 [Abstract] [Full Text] [Related]
18. Effect of antihypertensive therapy on serum lipids in newly diagnosed essential hypertensive men. Nandeesha H, Pavithran P, Madanmohan T. Angiology; 2009 Dec 15; 60(2):217-20. PubMed ID: 18445617 [Abstract] [Full Text] [Related]
19. Beneficial effects of the calcium antagonist isradipine on apolipoproteins in hypertensive patients. Lacourcière Y, Gagné C, Brun D, Poirier L, Dion D, Yardley C. Am J Hypertens; 1991 Feb 15; 4(2 Pt 2):181S-184S. PubMed ID: 1827016 [Abstract] [Full Text] [Related]
20. [Effect on lipids, lipoproteins and apoproteins of labetalol prescribed in doses of 400 mg/day in hypertensive patients. Double-blind versus placebo study]. Rouffy J, Bakir R, Chanu B, Djian F, Goy-Loeper J, Henry Amar M, Renon D, Pappo M. Pathol Biol (Paris); 1986 Apr 15; 34(4):253-8. PubMed ID: 3529000 [Abstract] [Full Text] [Related] Page: [Next] [New Search]